通过天眼查大数据分析，山东新华制药股份有限公司共对外投资了19家企业，参与招投标项目5000次， 知识产权方面有商标信息402条，专利信息524条，此外企业还拥有行政许可855个。 来源：金融界 新华制药最新一期业绩显示，截至2025一季报，公司营业总收入24.30亿元、同比减少1.81%，归属净利 润1.12亿元，同比减少20.99%，扣非净利润1.05亿元，同比减少23.74%，流动比率1.236、速动比率 0.872、资产负债率41.86%。 天眼查商业履历信息显示，山东新华制药股份有限公司，成立于1998年，位于淄博市，是一家以从事医 药制造业为主的企业。企业注册资本689776.535万人民币，实缴资本68240.7635万人民币。公司法定代 表人为贺同庆。 金融界消息 截至2025年8月15日收盘，新华制药（000756）报收于16.44元，上涨1.11%，换手率 2.24%，成交量11.05万手，成交金额1.81亿元。 资金流向方面，今日主力资金净流出1941.19万元，占比成交额10.74%。其中，超大单净流出1021.86万 元、占成交额5.66%，大单净流出919.33万元、占成交额5.0 ...

金融界消息 截至2025年8月14日收盘，新华制药（000756）报收于16.26元，下跌2.22%，换手率 2.72%，成交量13.41万手，成交金额2.20亿元。 资金流向方面，今日主力资金净流出4119.96万元，占比成交额18.7%。其中，超大单净流出2607.20万 元、占成交额11.84%，大单净流出1512.77万元、占成交额6.87%，中单净流出流入747.13万元、占成交 额3.39%，小单净流入3372.84万元、占成交额15.31%。 新华制药最新一期业绩显示，截至2025一季报，公司营业总收入24.30亿元、同比减少1.81%，归属净利 润1.12亿元，同比减少20.99%，扣非净利润1.05亿元，同比减少23.74%，流动比率1.236、速动比率 0.872、资产负债率41.86%。 天眼查商业履历信息显示，山东新华制药股份有限公司，成立于1998年，位于淄博市，是一家以从事医 药制造业为主的企业。企业注册资本689776.535万人民币，实缴资本68240.7635万人民币。公司法定代 表人为贺同庆。 通过天眼查大数据分析，山东新华制药股份有限公司共对外投资了19家企业，参与招投标 ...

格隆汇8月12日丨山东新华制药股份(00719.HK)宣布，公司将于2025年8月26日(星期二)上午九时三十分 在中国山东省淄博市高新区鲁泰大道1号公司会议室召开董事会会议，会议内容如下：1、审议及批准公 司及其附属公司截至2025年6月30日止六个月未经审计的中期业绩；及2、任何其他事宜，如适用。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 執行董事： 賀同慶先生（董事長） 徐文輝先生 侯 寧先生 獨立非執行董事： 潘廣成先生 朱建偉先生 淩沛學先生 張菁菁女士 董事會會議通知 山東新華製藥股份有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於二零二五年 八月二十六日（星期二）上午九時三十分在中華人民共和國（「中國」）山東省淄博市高新區 魯泰大道1號本公司會議室召開董事會會議，會議內容如下： 承董事會命 山東新華製藥股份有限公司 賀同慶先生 董事長 中國 淄博，二零二五年八月十二日 於本公告日期，本公司董事會由下列董事組成： 公告 非執行董事： 徐 列先生 張成勇先生 1、 審議及批准本公司及其附屬公司截至二零二五年六月三十日止六個月未經審計的中期 ...

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1][2] - Among the CFOs, those aged 40-50 constitute the majority at 36%, while 5% are over 60 years old, 33% are aged 50-60, and 26% are 40 years old or younger [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, 12% have an associate degree, and only 2% have a high school education [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The distribution of salaries indicates that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2][3] Group 1: Companies with Increased Holdings - Haotian International Construction (01341) saw the largest increase in holdings, up by 5.66% to a total of 58.15% [2] - Hang Seng China Enterprises (02828) experienced a 5.47% increase, bringing its holding to 6.12% [2] - The Yingfu Fund (02800) increased by 4.10%, resulting in a holding of 4.75% [2] - Meizhong Jiahe (02453) had a notable increase of 9.06% over five days, reaching a holding of 34.31% [3] - Shandong Molong (00568) increased by 5.40% to 59.14% [3] - Changfei Optical Fiber (06869) saw a 5.35% increase, with a holding of 49.42% [3] Group 2: Companies with Decreased Holdings - Yisou Technology (02550) experienced the largest decrease, down by 8.45% to 48.02% [2] - Longpan Technology (02465) decreased by 1.67%, resulting in a holding of 46.71% [2] - Shandong Xinhua Pharmaceutical (00719) saw a reduction of 1.05%, bringing its holding to 41.70% [2] - Over the last five days, Yisou Technology (02550) had a significant drop of 9.99% to 48.02% [3] - Shandong Xinhua Pharmaceutical (00719) also decreased by 2.95% to 41.70% [3] - Chongqing Steel (01053) saw a reduction of 2.65%, with a holding of 34.17% [3] Group 3: Long-term Trends - Over the past 20 days, Haotian International Construction (01341) had a substantial increase of 25.58%, reaching a holding of 58.15% [4] - Changfei Optical Fiber (06869) increased by 21.92% to 49.42% [4] - Dongfang Electric (01072) saw a 13.44% increase, with a holding of 40.54% [4]

Core Viewpoint - Xinhua Pharmaceutical's stock price decreased by 1.71% to 16.69 yuan, with a trading volume of 190,900 hands and a transaction amount of 321 million yuan [1] Company Overview - Xinhua Pharmaceutical is primarily engaged in the research, production, and sales of chemical raw materials, formulations, and pharmaceutical intermediates, covering various therapeutic areas including antipyretic and analgesic, cardiovascular, anti-infection, and nervous system [1] Recent Developments - On August 5, the company announced that its wholly-owned subsidiary, Xinda Pharmaceutical, received approval from the National Medical Products Administration for the registration certificate of Finasteride tablets, which are used to treat benign prostatic hyperplasia and are classified as a Category B drug under medical insurance [1] - Public data indicates that the sales revenue of this drug in Chinese public medical institutions is expected to be approximately 1.45 billion yuan in 2024 [1] Financial Flow - On the day of the stock price decline, the net outflow of main funds for Xinhua Pharmaceutical was 26.63 million yuan, with a cumulative net outflow of 90.37 million yuan over the past five days [1]

Core Insights - The report highlights significant changes in the shareholding ratios of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Increased Shareholding Ratios - The companies with the largest increases in shareholding ratios include: - Hang Seng China Enterprises (02828) with an increase of 4.29%, reaching a holding ratio of 19.02% [1][2] - Dongjiang Environmental (00895) with an increase of 2.08%, reaching a holding ratio of 42.98% [1][2] - Meizhong Jiahe (02453) with an increase of 2.02%, reaching a holding ratio of 32.46% [1][2] - Over the last five trading days, the top gainers in shareholding ratios were: - Hang Seng China Enterprises (02828) with an increase of 11.75% [5] - Changfei Optical Fiber (06869) with an increase of 7.15%, reaching a holding ratio of 45.78% [5] - Zhengzhou Bank (06196) with an increase of 3.95%, reaching a holding ratio of 51.58% [5] Group 2: Decreased Shareholding Ratios - The companies with the largest decreases in shareholding ratios include: - Shandong Molong (00568) with a decrease of 3.32%, holding 58.15% [3][4] - Kanglong Chemical (03759) with a decrease of 1.21%, holding 54.05% [3][4] - Green Leaf Pharmaceutical (02186) with a decrease of 1.09%, holding 39.33% [3][4] - Over the last five trading days, the top decliners in shareholding ratios were: - Shandong Xinhua Pharmaceutical (00719) with a decrease of 5.14%, holding 42.62% [6] - Guolian Minsheng (01456) with a decrease of 2.30%, holding 52.59% [6] - Dongfang Electric (01072) with a decrease of 2.06%, holding 40.71% [6] Group 3: Long-term Trends - Over the last 20 trading days, the companies with the largest increases in shareholding ratios included: - Hang Seng China Enterprises (02828) with an increase of 18.02%, holding 19.02% [8] - Changfei Optical Fiber (06869) with an increase of 17.40%, holding 45.78% [8] - Junda Co., Ltd. (02865) with an increase of 14.19%, holding 27.55% [8] - The companies with the largest decreases in shareholding ratios over the last 20 trading days included: - Shijiazhuang Octagon (09676) with a decrease of 13.12%, holding 9.51% [9] - Marco Digital Technology (01942) with a decrease of 9.35%, holding 43.30% [9] - Tigermed (03347) with a decrease of 8.65%, holding 58.37% [9]

证券日报网讯 8月5日晚间，新华制药（000756）发布公告称，近日，公司之全资子公司山东淄博新达 制药有限公司收到国家药品监督管理局核准签发的非那雄胺片《药品注册证书》。 ...

（文章来源：每日经济新闻） 新华制药（SZ 000756，收盘价：16.98元）8月5日晚间发布公告称，近日，山东新华制药股份有限公司 之全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的非那雄胺片《药品注册证 书》。产品名称为"非那雄胺片"。 2024年1至12月份，新华制药的营业收入构成为：化学药品制剂制造业占比48.1%，化学药品原药制造 业占比32.32%，医药中间体及其他占比19.59%。 ...